Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Overview
Vivos Therapeutics Inc is a specialized medical technology company dedicated to addressing sleep disordered breathing (SDB) with a focus on mild-to-moderate obstructive sleep apnea (OSA). Leveraging industry-specific technology and customized oral appliance therapy, the company offers a non-surgical, non-invasive, and low-cost solution that distinguishes it within the competitive landscape of sleep health and medical devices. Key industry terms such as "obstructive sleep apnea", "sleep disordered breathing", and "oral appliance therapy" underscore its commitment to innovative clinical solutions.
Business Model and Operations
The company operates through two core revenue streams. One stream involves the development, commercialization, and direct distribution of customized oral appliances that integrate proprietary clinical protocols. These protocols, often administered by specially trained dentists in collaboration with other healthcare professionals, provide an alternative therapy to traditional CPAP treatments. The second stream is driven by the company’s licensing of its intellectual property, allowing third-party manufacturers to produce therapeutic devices according to the specialized Vivos System guidelines.
Clinical Protocols and Healthcare Integration
At the heart of Vivos Therapeutics is its Vivos System, a treatment protocol that combines device customization with targeted clinical methodologies. Through its integrated healthcare network, the company connects general dentists, medical doctors, myofunctional therapists, and chiropractors, creating a collaborative ecosystem focused on treating SDB. This structure not only facilitates patient access to specialized care but also supports the standardization of care practices within the field of sleep medicine.
Innovation and Industry Positioning
Vivos Therapeutics distinguishes itself by emphasizing non-surgical and non-pharmaceutical approaches to managing OSA. Its focus on low-cost, patient-centric treatment solutions aims to enhance accessibility and compliance, contributing to its competitive positioning against conventional therapies such as CPAP devices. The company’s ongoing efforts to refine its treatment methodologies and expand its integrated network underscore its commitment to clinical excellence and technological advancement.
Research and Development Focus
Innovation remains central to Vivos Therapeutics' strategy. The development of customizable treatment protocols and proprietary oral appliances represents a blend of technical expertise and clinical insight. The company’s research and development efforts not only drive its product offerings forward but also position it as a key contributor within the sleep health arena. By collaborating with clinical experts and leveraging insights from real-world healthcare practices, Vivos continually refines its approach to meet evolving patient needs.
Market and Competitive Landscape
Operating within the broader medical device industry, Vivos Therapeutics faces the dual challenge of technological advancement and regulatory compliance. Its focus on offering a tangible alternative to surgical and pharmaceutical interventions sets it apart. Competitors may include traditional CPAP providers and other oral appliance manufacturers; however, Vivos’ integrated clinical protocols and licensing model offer a unique value proposition that enhances its industry credibility. The company’s strategy to work closely with an array of healthcare providers also reinforces its role as a pivotal player in specialized sleep disorder treatment.
Conclusion
In summary, Vivos Therapeutics Inc provides a distinct approach to managing mild-to-moderate OSA through the use of custom oral appliances and an integrated treatment protocol. Its operations, characterized by dual revenue pathways and a comprehensive healthcare network, illustrate a robust business model suited for the evolving landscape of sleep medicine. This detailed look at its operations, innovation practices, and market positioning provides investors and industry observers with a clear understanding of its core competencies and strategic framework.
Vivos Therapeutics (NASDAQ: VVOS) reported strong financial results for full year 2024, with revenue increasing 9% to $15.0 million from $13.8 million in 2023. Product revenue grew 26% year-over-year, while operating expenses decreased 21% to $20.2 million.
The company maintained a 60% gross margin, with gross profit reaching $9.0 million. Operating loss decreased significantly by 35% to $11.2 million. Cash position stood at $6.3 million after raising $17.9 million through equity transactions in 2024.
Notable achievements include FDA 510(k) clearance for the DNA appliance to treat moderate to severe OSA in children ages 6-17, complementing their 2023 clearance for adult treatment. Patient treatments increased to 58,000 worldwide, up from 42,000 in 2023. The company implemented a strategic pivot towards contractual, profit-sharing alliances with sleep healthcare providers, starting with Rebis Health Holdings, expecting to increase revenue per case by 4-6 times with 50% contribution margins.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders treatments, has scheduled its full year 2024 financial results release for Monday, March 31, 2025, after market close.
The company will host a conference call at 5:00 PM ET on the same day to discuss the results and provide updates on recent milestones. Investors can join via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until April 14, 2025, using passcode 1103883. The webcast can be accessed through Vivos' investor relations website, with a 30-day archive available.
Vivos Therapeutics (NASDAQ: VVOS) announced significant expansions and achievements in its strategic alliance with Rebis Health Holdings. The company is extending its FDA-cleared Vivos CARE treatment for OSA into two additional Denver market facilities and plans nationwide expansion through sleep center affiliations and acquisitions.
Initial data shows a 64% acceptance rate for Vivos treatment, with patients preferring it nearly 2:1 over CPAP. The company reports average per case revenue of over $4,700 with gross margins around 70% before profit sharing with Rebis. The new business model shows potential for up to four times greater profit per case compared to their previous distribution model.
The expansion includes new locations in Highlands Ranch and Westminster, expected to be operational by April. Vivos is exploring partnerships with over 2,500 accredited sleep medicine groups nationwide, aiming to accelerate revenue growth and achieve cash flow-positive operations.
Vivos Therapeutics (NASDAQ: VVOS), a medical device and technology company focused on sleep-related breathing disorders, has announced a fireside chat scheduled for February 18, 2025, at 12:00 pm ET. CEO Kirk Huntsman will engage with Water Tower Research's senior analyst Do Kim to discuss several key topics.
The discussion will cover the company's Vivos CARE devices for treating obstructive sleep apnea (OSA) and snoring in adults, as well as moderate to severe OSA in children aged 6-17. Key points to be addressed include the company's strategic shift to a medical-based business model, efforts to establish partnerships with physician-based sleep groups, OSA market dynamics, and the positioning of Vivos CARE devices in OSA treatment.
The event will be listen-only, with a replay available for 30 days in the Investor Relations section of the Vivos website.
Vivos Therapeutics (NASDAQ: VVOS) has announced a $3.5 million registered direct offering priced at-the-market, selling 709,220 shares at $4.935 per share. The company will also issue unregistered short-term warrants in a concurrent private placement to purchase up to 709,220 shares at $4.81 per share, exercisable for two years. If fully exercised, these warrants could generate additional gross proceeds of approximately $3.4 million.
The offering is expected to close around December 24, 2024, with H.C. Wainwright & Co. serving as the exclusive placement agent. Vivos plans to use the net proceeds for working capital and general corporate purposes. The shares are being offered under a shelf registration statement, while the warrants are being issued through a private placement under Section 4(a)(2) of the Securities Act.
Vivos Therapeutics (NASDAQ: VVOS) reported strong Q3 2024 financial results with revenue increasing 17% to $3.9 million compared to Q3 2023. Gross profit reached $2.3 million with margins improving to 60%. Operating expenses decreased by 8%, marking the ninth consecutive quarter of year-over-year reductions. The company achieved significant milestones including FDA clearance for treating moderate to severe OSA in children ages 6-17 and new AMA CPT codes for their devices effective January 2024. Patient treatments increased to over 47,000 worldwide, with more than 2,000 trained dentists. The company projects achieving positive cash flow from operations by mid-2025.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company focused on sleep-related breathing disorders treatment, announced its plans to release Q3 2024 financial results after market close on November 14, 2024. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments. Investors can access the call via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until November 29, 2024, and a live webcast can be accessed through the company's website.
Vivos Therapeutics (NASDAQ: VVOS) has announced that the American Medical Association (AMA) has issued new CPT® medical codes for all Vivos CARE oral medical devices, effective January 1, 2025. This development is expected to facilitate coverage and reimbursement by commercial medical insurance payers for the treatment of obstructive sleep apnea (OSA) in adults and children.
Vivos Chairman and CEO, Kirk Huntsman, stated that this approval will enable a larger number of patients to access their proprietary airway remodeling technology. The company believes this, along with recent regulatory approvals and their new alliance-based marketing and distribution model, will improve their position to drive revenue growth.
The AMA's CPT® 2025 code set includes 420 overall updates, with 270 new codes, 112 deletions, and 38 revisions. This approval follows Vivos' recent Medicare coverage approval and is seen as a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17.
Vivos Therapeutics (NASDAQ: VVOS), a medical device company specializing in sleep-related breathing disorders treatments, has announced a $4.3 million registered direct offering of common stock. The offering involves the sale of 1,363,812 shares at $3.15 per share, priced at-the-market under Nasdaq rules. No warrants are being issued. The offering is expected to close around September 20, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. Vivos intends to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.
Vivos Therapeutics (NASDAQ: VVOS) has received a groundbreaking FDA 510(k) clearance for its DNA appliance to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children aged 6 to 17. This is believed to be the first such clearance for an oral medical device in pediatric OSA treatment. The approval is based on a multi-site clinical trial that showed significant improvements in OSA symptoms and airway volumes.
Key findings from the study include:
- 50% reduction in sleep-related breathing disorder symptoms
- 58% decrease in snoring
- 62.7% improvement in moderate and severe AHI measurements
- 40% increase in airway volumes
Vivos aims to disrupt the pediatric OSA market, estimated at 10.1 million U.S. children, with its non-invasive, safe, and effective treatment option.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What is the core focus of Vivos Therapeutics Inc?
How does the company generate its revenue?
What is the Vivos System?
Who are the primary beneficiaries of Vivos Therapeutics' services?
What distinguishes Vivos Therapeutics from traditional CPAP therapies?
How does Vivos Therapeutics integrate with the healthcare ecosystem?
What market challenges does Vivos Therapeutics face?
How does Vivos Therapeutics demonstrate industry expertise?
